Revive Therapeutics (31R) Stock Price & Analysis
31R Stock Chart & Stats
- Day’s Range
- EUR 0.01 - EUR 0.02
- 52-Week Range
- EUR 0.00 - EUR 0.06
- Previous Close
- EUR 0.01
- Volume
- N/A
- Average Volume (3M)
- 5,963
- Market Cap
- EUR 5.35M
- Enterprise Value
- EUR 15.30M
- Total Cash (Recent Filing)
- EUR 22.66K
- Total Debt (Recent Filing)
- EUR 70.77K
- Price to Earnings (P/E)
- ―
- Beta
- -28.16
- Next Earnings
- Nov 27, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Debt Burden
Very low debt reduces near-term refinancing pressure and interest obligations while the company remains in development. This provides some financial flexibility to direct available resources toward clinical programs, intellectual property, and regulatory work, although it does not eliminate broader funding needs.
Improving Losses And Cash Burn
The sharp improvement in annual losses and operating cash burn suggests tighter spending or a smaller operating footprint. If sustained, this trend could extend the company’s available resources and improve execution capacity while its drug candidates progress through development.
Bucillamine Development Platform
Revive is building a broader development and intellectual-property platform around bucillamine, including two FDA Orphan Drug Designations and potential medical-countermeasure uses. Multiple indications and partnering pathways could increase strategic value if research and regulatory progress continues.
Bears Say
No Commercial Revenue
The absence of revenue means Revive has not yet demonstrated commercial demand or an operating model that funds itself. Until a candidate reaches approval and sales, future progress depends on development execution and access to capital rather than recurring customer income.
Negative Shareholders’ Equity
Negative equity indicates that accumulated losses have materially weakened the company’s capital base. This reduces balance-sheet resilience and leaves less financial capacity to absorb setbacks, support development spending, or pursue opportunities without additional financing.
Persistent Negative Cash Flow
Consistently negative operating and free cash flow show that current activities do not generate the funds required to sustain operations. Even with improved burn, continued external financing may be necessary, creating ongoing funding pressure as clinical and regulatory work advances.
Revive Therapeutics News
31R FAQ
What was Revive Therapeutics’s price range in the past 12 months?
What is Revive Therapeutics’s market cap?
When is Revive Therapeutics’s upcoming earnings report date?
How were Revive Therapeutics’s earnings last quarter?
Is Revive Therapeutics overvalued?
Does Revive Therapeutics pay dividends?
What is Revive Therapeutics’s EPS estimate?
How many shares outstanding does Revive Therapeutics have?
What happened to Revive Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Revive Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Revive Therapeutics
Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory ailments. Currently, it is advancing Bucillamine through a Phase 3 clinical study for infectious diseases like influenza and COVID-19. Its psychedelic programs include Psilocybin, undergoing a Phase 1 clinical study for methamphetamine use disorder, and Psilocin, which is being investigated for applications in depression, anxiety, bipolar disorder, bulimia, anorexia nervosa, and other related conditions. Additionally, Revive is exploring cannabidiol for autoimmune hepatitis and for addressing ischemia and reperfusion injury following organ transplantation. The company has forged several significant research collaborations: with PharmaTher Inc. for psilocybin development in cancer treatment, the discovery of other psychedelic compound applications, and a psilocybin microneedle patch; with North Carolina State University to develop a biosynthetic psilocybin based on a natural enzymatic platform; with the University of California, San Francisco, to investigate Bucillamine for severe COVID-19; and with the University of Health Sciences Antigua for clinical research into psychedelics. Established in 2012, Revive Therapeutics Ltd. is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Michael Frank
- Employees
- 2
- Website
- www.revivethera.com
- Address
- The Canadian Venture Building, Toronto, ON, M5C 1P1, CA
Revive Therapeutics (31R) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 5 | 3 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 8 | 0 | 0 |
